Market closedNon-fractional

Prothena/PRTA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Prothena

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Ticker

PRTA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Dublin, Ireland

Employees

173

Prothena Metrics

BasicAdvanced
$1.3B
Market cap
-
P/E ratio
-$3.22
EPS
0.30
Beta
-
Dividend rate
$1.3B
0.3
13.079
12.631
2.015
2.487
-19.81%
-31.07%
14.619
2.6
2.6
-8.036
62.51%
23.32%
367.77%
1.20%

What the Analysts think about Prothena

Analyst Ratings

Majority rating from 9 analysts.
Buy

Prothena Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$72M
7.12%
Profit margin
0.00%
-100.00%

Prothena Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 11.55%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.03
$0.38
-$1.26
-$1.34
-
Expected
-$1.00
-$0.32
-$1.22
-$1.20
-$1.22
Surprise
3.42%
-218.01%
3.56%
11.55%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Prothena stock?

Prothena (PRTA) has a market cap of $1.3B as of July 23, 2024.

What is the P/E ratio for Prothena stock?

The price to earnings (P/E) ratio for Prothena (PRTA) stock is 0 as of July 23, 2024.

Does Prothena stock pay dividends?

No, Prothena (PRTA) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Prothena dividend payment date?

Prothena (PRTA) stock does not pay dividends to its shareholders.

What is the beta indicator for Prothena?

Prothena (PRTA) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Prothena stock

Buy or sell Prothena stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing